| 000 -LEADER |
|---|
| fixed length control field |
03439nam a22004575i 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
978-3-7643-7726-7 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
DE-He213 |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20161121230601.0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
|---|
| fixed length control field |
cr nn 008mamaa |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
100529s2005 sz | s |||| 0|eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9783764377267 |
| -- |
978-3-7643-7726-7 |
| 024 7# - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.1007/978-3-7643-7726-7 |
| Source of number or code |
doi |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
R1 |
| 072 #7 - SUBJECT CATEGORY CODE |
|---|
| Subject category code |
MB |
| Source |
bicssc |
| 072 #7 - SUBJECT CATEGORY CODE |
|---|
| Subject category code |
MED000000 |
| Source |
bisacsh |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
610 |
| Edition number |
23 |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Antirheumatic Therapy: Actions and Outcomes |
| Medium |
[electronic resource] / |
| Statement of responsibility, etc. |
edited by Richard O. Day, Daniel E. F�rst, Piet L. C. M. van Riel, Barry Bresnihan. |
| 264 1# - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Place of production, publication, distribution, manufacture |
Basel : |
| Name of producer, publisher, distributor, manufacturer |
Birkh�user Basel, |
| Date of production, publication, distribution, manufacture, or copyright notice |
2005. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
XIII, 343 p. |
| Other physical details |
online resource. |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Content type code |
txt |
| Source |
rdacontent |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
computer |
| Media type code |
c |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
online resource |
| Carrier type code |
cr |
| Source |
rdacarrier |
| 347 ## - DIGITAL FILE CHARACTERISTICS |
|---|
| File type |
text file |
| Encoding format |
PDF |
| Source |
rda1 |
| 490 ## - SERIES STATEMENT |
|---|
| Series statement |
Progress in Inflammation Research0 |
| 505 ## - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
Medicinal chemistry of the disease modifying anti-rheumatic drugs -- Targeting DMARD therapy -- Pharmacoeconomic properties of disease-modifying antirheumatic drugs -- Future molecular targets -- Hydroxychloroquine -- Sulfasalazine -- Parenteral gold -- Azathioprine -- Methotrexate -- Leflunomide -- Cyclosporin -- Tetracyclines -- Systemic glucocorticoids in rheumatoid arthritis -- TNF-? inhibitors -- Anakinra in rheumatoid arthritis -- Combination therapy -- Hematopoietic stem cell transplantation for the treatment of severe autoimmune diseases. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
Our goal for this book is to examine the contemporary therapy of rheumatoid arthritis (RA) from the increasingly important perspective of impact upon quality of life, costs and long-term health outcomes. For too long the focus has been on short� term, symptomatic, and surrogate indicator outcomes. Yet RA is a life-long disor� der with the majority of impact on an individual patient many years following onset. Further, even in the short-term, researchers and rheumatologists have tended to emphasize measurements of disease activity such as joint counts, ESR and physi� cian's opinion as to the amount of disease activity present. It is only relatively recently that measures of structural damage, quality of life and impact on broad domains of health have been given increasing emphasis. Also, the significance of early treatment of RA in order to optimise long-term outcomes has a relatively short history [1]. We have been focussed on the disease processes as surrogates for long� term outcomes. Until the short-term process measures are validated as surrogates of long-term effects we should also turn our attention to outcomes of disease and the impact of our management on those outcomes [2). Inour view, this book is especially timely. We are at the dawn of a revolution in the management of RA and other complex immunological inflammatory disorders because their molecular, genetic and environmental mechanisms are being unrav� elled. Inthe process, we are revealing a substantial number of novel and significant targets for pharmacotherapy. 0 |
| -- |
Med |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Med |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Med |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Day |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Relator term |
editor.1 |
| Personal name |
F�r |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Relator term |
editor.1 |
| Personal name |
Riel |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Relator term |
editor.1 |
| Personal name |
Bres |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Relator term |
editor.2 |
| Personal name |
Spri |
| 710 ## - ADDED ENTRY--CORPORATE NAME |
|---|
| Title of a work |
Spri |
| 773 ## - HOST ITEM ENTRY |
|---|
| Relationship information |
Prin |
| 776 ## - ADDITIONAL PHYSICAL FORM ENTRY |
|---|
| International Standard Book Number |
9783764365950 0 |
| Main entry heading |
Prog |
| 830 ## - SERIES ADDED ENTRY--UNIFORM TITLE |
|---|
| -- |
http |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| Host name |
ZDB- |
| 912 ## - |
|---|
| -- |
Medi |
